Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Alpha Cognition (NASDAQ: ACOG) demonstrated significant growth in 2024, successfully raising $52.8 million and completing its NASDAQ uplisting. The company achieved several key milestones, including completing commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), securing a U.S. patent extending protection through 2044, and finalizing phase one of a Department of Defense-funded study for head trauma treatment.
Notable achievements include a successful launch in the U.S. Long-Term Care (LTC) market, estimated at $2 billion, and securing a $44 million licensing agreement for Asia. The company reports positive initial physician feedback and is actively building international partnerships to diversify revenue streams.
Alpha Cognition (NASDAQ: ACOG) ha dimostrato una crescita significativa nel 2024, raccogliendo con successo 52,8 milioni di dollari e completando il suo passaggio al NASDAQ. L'azienda ha raggiunto diversi traguardi chiave, tra cui la conclusione della produzione commerciale per il suo prodotto di punta ZUNVEYL (benzgalantamina), l'ottenimento di un brevetto negli Stati Uniti che estende la protezione fino al 2044 e la finalizzazione della fase uno di uno studio finanziato dal Dipartimento della Difesa per il trattamento dei traumi cranici.
Tra i risultati notevoli ci sono un lancio di successo nel mercato statunitense della Long-Term Care (LTC), stimato in 2 miliardi di dollari, e la stipula di un accordo di licenza di 44 milioni di dollari per l'Asia. L'azienda riporta un feedback iniziale positivo da parte dei medici e sta attivamente costruendo partnership internazionali per diversificare le fonti di reddito.
Alpha Cognition (NASDAQ: ACOG) demostró un crecimiento significativo en 2024, recaudando exitosamente 52.8 millones de dólares y completando su uplisting en NASDAQ. La compañía alcanzó varios hitos clave, incluyendo la finalización de la fabricación comercial de su producto principal ZUNVEYL (benzgalantamina), asegurando una patente en EE. UU. que extiende la protección hasta 2044, y finalizando la fase uno de un estudio financiado por el Departamento de Defensa para el tratamiento de traumas craneales.
Logros notables incluyen un lanzamiento exitoso en el mercado de Cuidado a Largo Plazo (LTC) de EE. UU., estimado en 2 mil millones de dólares, y la obtención de un acuerdo de licencia de 44 millones de dólares para Asia. La compañía informa de comentarios iniciales positivos por parte de los médicos y está construyendo activamente asociaciones internacionales para diversificar sus fuentes de ingresos.
알파 코그니션 (NASDAQ: ACOG)은 2024년에 상당한 성장을 보여주며 5,280만 달러를 성공적으로 조달하고 NASDAQ 상장을 완료했습니다. 이 회사는 주요 제품 ZUNVEYL (벤즈갈란타민)의 상업적 제조를 완료하고, 2044년까지 보호를 연장하는 미국 특허를 확보하며, 두부 외상 치료를 위한 국방부 자금 지원 연구의 1단계를 마무리하는 등 여러 주요 이정표를 달성했습니다.
주목할 만한 성과로는 20억 달러로 추정되는 미국 장기 요양(LTC) 시장에서의 성공적인 출시와 아시아를 위한 4,400만 달러의 라이센스 계약 체결이 있습니다. 이 회사는 초기 의사 피드백이 긍정적이라고 보고하며, 수익원을 다각화하기 위해 국제 파트너십을 적극적으로 구축하고 있습니다.
Alpha Cognition (NASDAQ: ACOG) a montré une croissance significative en 2024, levant avec succès 52,8 millions de dollars et complétant son inscription au NASDAQ. L'entreprise a atteint plusieurs jalons clés, notamment l'achèvement de la fabrication commerciale de son produit phare ZUNVEYL (benzgalantamine), l'obtention d'un brevet américain prolongeant la protection jusqu'en 2044 et la finalisation de la phase un d'une étude financée par le Département de la Défense pour le traitement des traumatismes crâniens.
Parmi les réalisations notables, on trouve un lancement réussi sur le marché américain des soins de longue durée (LTC), estimé à 2 milliards de dollars, et la sécurisation d'un accord de licence de 44 millions de dollars pour l'Asie. L'entreprise rapporte des retours positifs initiaux de médecins et construit activement des partenariats internationaux pour diversifier ses sources de revenus.
Alpha Cognition (NASDAQ: ACOG) zeigte 2024 ein signifikantes Wachstum und konnte erfolgreich 52,8 Millionen Dollar aufbringen sowie sein NASDAQ-Listing abschließen. Das Unternehmen erreichte mehrere wichtige Meilensteine, darunter den Abschluss der kommerziellen Herstellung seines Hauptprodukts ZUNVEYL (Benzgalantamin), die Sicherung eines US-Patents, das den Schutz bis 2044 verlängert, und den Abschluss der ersten Phase einer vom Verteidigungsministerium finanzierten Studie zur Behandlung von Kopfverletzungen.
Zu den bemerkenswerten Erfolgen gehört ein erfolgreicher Start im US-Markt für Langzeitpflege (LTC), der auf 2 Milliarden Dollar geschätzt wird, sowie die Sicherung eines 44 Millionen Dollar Lizenzvertrags für Asien. Das Unternehmen berichtet von positiven ersten Rückmeldungen von Ärzten und baut aktiv internationale Partnerschaften auf, um die Einnahmequellen zu diversifizieren.
- Raised $52.8M and completed NASDAQ uplisting
- Secured $44M licensing deal for Asian market
- Completed commercial manufacturing for ZUNVEYL
- Extended patent protection through 2044
- Successfully launched in $2B LTC market
- Positive physician feedback in initial launch
- None.
Dallas, Texas--(Newsfile Corp. - April 1, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Successfully launched in U.S. LTC market; raised
$52.8M , uplisted to Nasdaq (ACOG), and secured patent protection through 2044. - Signed
$44M licensing deal for Asia; building international partnerships to diversify revenue and reduce risk. - Strong start in
$2B LTC market with experienced sales team; positive initial physician feedback driving awareness and adoption.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247008
FAQ
What major funding did Alpha Cognition (ACOG) secure in 2024?
How long is ACOG's patent protection for ZUNVEYL extended?
What is the value of ACOG's Asian licensing deal?
What is the estimated market size for ACOG's LTC segment?
What progress has ACOG made with the Department of Defense?
